These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 15622778)
1. [Phase III clinical trial on domestic amsacrine in patients with acute leukemias]. Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):61-4. PubMed ID: 15622778 [TBL] [Abstract][Full Text] [Related]
2. [Phase II clinical trial of domestic amsacrine in patients with acute leukemias. Cooperative Group for Treating Acute Leukemias with Domestic m-AMSA]. Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):80-4. PubMed ID: 8404329 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175 [TBL] [Abstract][Full Text] [Related]
4. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia]. Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062 [TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study. Schiffer CA; Davis RB; Mayer RJ; Peterson BA; Lee EJ Cancer Treat Rep; 1987 Sep; 71(9):879-80. PubMed ID: 3621225 [No Abstract] [Full Text] [Related]
7. Review of amsacrine, an investigational antineoplastic agent. Grove WR; Fortner CL; Wiernik PH Clin Pharm; 1982; 1(4):320-6. PubMed ID: 6764391 [TBL] [Abstract][Full Text] [Related]
8. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Meloni G; Vignetti M; Avvisati G; Capria S; Micozzi A; Giona F; Mandelli F Bone Marrow Transplant; 1996 Oct; 18(4):693-8. PubMed ID: 8899182 [TBL] [Abstract][Full Text] [Related]
9. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. Winton EF; Hearn EB; Martelo O; Presant CA; Adler S; Vogler WR; Raney M; Logan T; Silberman HM; Omura GA Cancer Treat Rep; 1985; 69(7-8):807-11. PubMed ID: 2410119 [TBL] [Abstract][Full Text] [Related]
10. [Phase III clinical trial on meisoindico in the treatment of chronic myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi; 1997 Feb; 18(2):69-72. PubMed ID: 15622780 [TBL] [Abstract][Full Text] [Related]
11. [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies]. Wu DP; Tang XW; Sun AN; Qiu HY; Fu ZZ; Ma R; Ruan CG Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):599-601. PubMed ID: 14690573 [TBL] [Abstract][Full Text] [Related]
12. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA. Jehn U; Heinemann V Anticancer Res; 1991; 11(2):705-11. PubMed ID: 2064323 [TBL] [Abstract][Full Text] [Related]
13. Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia. Zohren F; Czibere A; Bruns I; Fenk R; Schroeder T; Gräf T; Haas R; Kobbe G Bone Marrow Transplant; 2009 Dec; 44(12):785-92. PubMed ID: 19430496 [TBL] [Abstract][Full Text] [Related]
14. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial. Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793 [TBL] [Abstract][Full Text] [Related]
15. [Allogeneic hematopoietic stem cell transplantation following reduced intensity conditioning regimen for treatment of refractory leukemia]. Jiang JL; Yan SK; Yang J; Cai Y; Wan LP; Qin YW; Wang C Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):517-21. PubMed ID: 19112913 [TBL] [Abstract][Full Text] [Related]
16. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of bisantrene in relapsed/refractory acute non lymphoid leukemias (ANLL). Tosi P; Visani G; Colombini R; Verlicchi F; Benfenati D; Cenacchi A; Russo D; Zuffa E; Papadopulu P; Tura S Haematologica; 1989; 74(6):555-8. PubMed ID: 2628237 [TBL] [Abstract][Full Text] [Related]
18. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults]. Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091 [TBL] [Abstract][Full Text] [Related]
19. Amsacrine evaluation. Van Mouwerik TJ; Caines PM; Ballentine R Drug Intell Clin Pharm; 1987 Apr; 21(4):330-4. PubMed ID: 3552546 [TBL] [Abstract][Full Text] [Related]
20. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]